DATE: November 21, 2019
TIME: 9:00am PST, 12:00pm EST
Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobulins in the bone marrow.
Today there are many treatment modalities ongoing targeting the myeloma microenvironment, but especially immunotherapy seems to be a promising approach.
Immune checkpoints are critical components in the regulation of immune cell responses. If immune cells are activated due to the contact to an antigen, they also need to be controlled to prevent an overactive immune response. These control checkpoints are often over-expressed in cancer cells and therefore protect them from the tumour-specific immune response enabling tumour immune escape.
We investigate the role of the PD-1/PD-L1 immune checkpoint during myeloma disease progression and determine combinatorial approaches of immunotherapeutic drugs to increase myeloma cell killing efficiency.
- Identify tumour immune microenvironment
- Examine immunotherapeutic strategies for hematologic malignancies
- Discuss flow cytometry to investigate immune cell regulation in multiple myeloma
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.